Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ADH1B | P00325 | 1/20 | 0.48 |
| ▸ | ADH1C | P00326 | 1/20 | 0.48 |
| ▸ | ADH1A | P07327 | 1/20 | 0.48 |
| ▸ | ADH7 | P40394 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24288430 | 1.00 | SIGMAR1 (0.53) | SIGMAR1ACEEPHX1ADH1BADH1C | |
| SCHEMBL8694353 | 0.84 | F2 (0.47) | ACECAPN1 | |
| SCHEMBL12468722 | 0.83 | SIGMAR1 (0.56) | SIGMAR1ACEEPHX1CAPN1MEN1 | |
| SCHEMBL18494852 | 0.83 | ACE (0.49) | ACEEPHX1CAPN1MEN1KMT2A | |
| SCHEMBL4314482 | 0.83 | SIGMAR1 (0.56) | SIGMAR1ACEEPHX1CAPN1MEN1 | |
| SCHEMBL29255909 | 0.83 | SIGMAR1 (0.47) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL16944013 | 0.83 | ACE (0.49) | ACEEPHX1CAPN1MEN1KMT2A | |
| SCHEMBL8245648 | 0.83 | ADH1B (0.47) | SIGMAR1ACEADH1BADH1CADH1A | |
| SCHEMBL16372685 | 0.83 | ADH1B (0.47) | SIGMAR1ACEADH1BADH1CADH1A | |
| SCHEMBL21654011 | 0.81 | CAPN1 (0.49) | SIGMAR1ACEEPHX1CAPN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106074591-B | RNA interference in ocular symptoms | 菲奥医药公司 | 2020-01-14 | — | — | CN | disclosed |
| US-7462608-B2 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20050197320-A1 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197320-A1 | Non nucleoside reverse transcriptase inhibitors | TYMP, PNP, ITPA | SIGMAR1 1593/4885ACE 241/4885EPHX1 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.